Skip to search formSkip to main contentSkip to account menu

bortezomib

Known as: Bortezomib [Chemical/Ingredient], N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid 
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that… 
National Institutes of Health

Related topics

Related topics

31 relations
Angiogenesis InhibitionBortezomib-Dexamethasone RegimenBortezomib/Cyclophosphamide/Dexamethasone RegimenBortezomib/Dexamethasone/Lenalidomide Regimen

Broader (1)

Antineoplastic Agents

Narrower (4)

LDP-341MLN341PS 341Velcade

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells.
Highly Cited
2013
Highly Cited
2013
Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Multiple myeloma accounts for approximately 10% of hematologic malignancies. 
Highly Cited
2012
Highly Cited
2012
Immune Mechanism of the Antitumor Effects Generated by Bortezomib
Bortezomib, a proteasome inhibitor, is a chemotherapeutic drug that is commonly used to treat a variety of human cancers. The… 
Highly Cited
2010
Highly Cited
2010
Cardiovascular , Pulmonary and Renal Pathology Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib
From the Departments of Immunology,* Histology and Embryology, and Pathology, Center of Biostructure Research, Medical University… 
Review
2009
Review
2009
Multiple myeloma
Highly Cited
2007
Highly Cited
2007
Unexpected cardiotoxicity in haematological bortezomib treated patients
Bortezomib is an antitumor compound that inhibits proteasome activity. It is able to impair the activation of nuclear factor (NF… 
Highly Cited
2005
Highly Cited
2005
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in… 
Highly Cited
2005
Highly Cited
2005
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim
Previously, we showed that the proteasome inhibitor bortezomib/Velcade (formerly PS-341) synergizes with the protein tumor… 
Highly Cited
2005
Highly Cited
2005
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Patients with metastatic melanoma or multiple myeloma have a dismal prognosis because these aggressive malignancies resist… 
Highly Cited
2001
Highly Cited
2001
Chemically L-phenylalaninamide-modified monolithic silica column prepared by a sol-gel process for enantioseparation of dansyl amino acids by ligand exchange-capillary electrochromatography.
A new type of chiral monolithic column was successfully developed for the enantioseparation of dansyl amino acids by ligand… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)